Sara Bjursten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Bjursten has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Lars Ny
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
2 shared publications- Ana Carneiro
Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Comprehensive Cancer Center, Lund, Sweden; Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden
1 shared publication - Andrew Josef Ewald
Johns Hopkins University 1 Department of Cell Biology, School of Medicine Baltimore, Maryland
1 shared publication Ankur Pandita
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
1 shared publication- Ankur Pandita
Wallenberg Laboratory for Cardiovascular Research, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
1 shared publication Anna Rudin
Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
1 shared publication
Latest Publications
- Open Access
- 24 May 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 243, 116833
Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma: A retrospective cohort study
- 24 May 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 243, 116833
Open AccessTime of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma: A retrospective cohort study
- Open Access
- 2 January 2024
- Published by Elsevier in EBioMedicine
- Vol. 100, 104955
Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor–induced CNS inflammation
- 2 January 2024
- Published by Elsevier in EBioMedicine
- Vol. 100, 104955
Open AccessConcentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor–induced CNS inflammation
- 1 November 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (11) , 2023-2038
Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma
- 1 November 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (11) , 2023-2038
Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma